A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocationassociated recurrent/metastatic sarcomas-NCIC-CTG IND 200

Quincy S.C. Chu, T. O. Nielsen, T. Alcindor, A. Gupta, M. Endo, A. Goytain, H. Xu, S. Verma, R. Tozer, M. Knowling, V. B. Bramwell, J. Powers, L. K. Seymour, E. A. Eisenhauer

研究成果: Contribution to journalArticle査読

28 被引用数 (Scopus)

抄録

Background: A subgroup of sarcomas is characterized by defining chromosomal translocations, creating fusion transcription factor oncogenes. Resultant fusion oncoproteins associate with chromatin-modifying complexes containing histone deacetylases (HDAC), and lead to epigenetic transcriptional dysregulation. HDAC inhibitors were shown to be effective in vitro, reversing gene repression by these complexes, restoring PTEN expression and apoptosis via the PI3K/Akt/mTOR pathway. Patients and methods: SB939 is an oral inhibitor of classes 1 and 2 HDAC. Eligible patients with recurrent or metastatic translocation-associated sarcoma (TAS) by local pathology were treated with 60 mg/day every other day for 3 of 4 weeks. Central pathology review was conducted with fusion oncogenes characterized, and HDAC2 expression correlated with efficacy in pre-specified methods. Results: Twenty-two patients were treated with a median of 2 cycles. Fourteen patients were assessable for response with confirmed specific chromosomal translocations; 8 had a best response of stable disease (SD) (median duration 5.4 months) with no confirmed objective responses. The 3-month progression-free survival (PFS) rate was 49%. Among those with HDAC2 score ≥5, 7/10 had SD, versus 0/3 with HDAC2 score <5. SB939 was considered as well tolerated with <10% patients experienced ≥grade 3 toxicity. Conclusion: This study was stopped prematurely due to prolonged unavailability of SB939. No objective responses were seen. Although the observed SD in HDAC2 high patients was interesting, due to the small sample size, no definitive conclusion can be drawn about the efficacy of SB939 in this patient population.

本文言語英語
ページ(範囲)973-981
ページ数9
ジャーナルAnnals of Oncology
26
5
DOI
出版ステータス出版済み - 5 1 2015

All Science Journal Classification (ASJC) codes

  • 血液学
  • 腫瘍学

フィンガープリント

「A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocationassociated recurrent/metastatic sarcomas-NCIC-CTG IND 200」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル